LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

InflaRx NV

Fermé

0.8

Résumé

Variation du prix de l'action

24h

Actuel

Min

0.74

Max

0.82

Chiffres clés

By Trading Economics

Revenu

-3.2M

-8.3M

BPA

-0.13

Marge bénéficiaire

1,208,456.738

Employés

74

EBITDA

-3.2M

-8.2M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+594.05% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-59M

54M

Ouverture précédente

0.8

Clôture précédente

0.8

Score Technique

By Trading Central

Confiance

Bearish Evidence

InflaRx NV Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

27 juin 2025, 20:51 UTC

Résultats

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 juin 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27 juin 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27 juin 2025, 20:48 UTC

Market Talk

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27 juin 2025, 20:46 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27 juin 2025, 20:46 UTC

Market Talk

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27 juin 2025, 19:31 UTC

Market Talk

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27 juin 2025, 19:19 UTC

Market Talk

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27 juin 2025, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27 juin 2025, 18:57 UTC

Acquisitions, Fusions, Rachats

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27 juin 2025, 18:57 UTC

Acquisitions, Fusions, Rachats

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27 juin 2025, 18:57 UTC

Acquisitions, Fusions, Rachats

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27 juin 2025, 18:57 UTC

Acquisitions, Fusions, Rachats

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 juin 2025, 18:57 UTC

Acquisitions, Fusions, Rachats

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 juin 2025, 18:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 juin 2025, 18:42 UTC

Market Talk

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27 juin 2025, 18:39 UTC

Market Talk
Résultats

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27 juin 2025, 18:29 UTC

Market Talk

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27 juin 2025, 18:18 UTC

Market Talk

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27 juin 2025, 18:16 UTC

Market Talk

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27 juin 2025, 17:16 UTC

Market Talk

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27 juin 2025, 17:08 UTC

Résultats

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27 juin 2025, 16:52 UTC

Acquisitions, Fusions, Rachats

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27 juin 2025, 16:22 UTC

Résultats

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 juin 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

27 juin 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27 juin 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

27 juin 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

27 juin 2025, 15:59 UTC

Market Talk

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27 juin 2025, 15:56 UTC

Market Talk

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Comparaison

Variation de prix

InflaRx NV prévision

Objectif de Prix

By TipRanks

594.05% hausse

Prévisions sur 12 Mois

Moyen 5.83 USD  594.05%

Haut 10 USD

Bas 2 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

7 ratings

6

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

1.29 / 1.85Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Neutral Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos InflaRx NV

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.